0
Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

1
INFLUENTIAL PUBLICATIONS   |    
Bibliography: for Psychopharmacology: Treatment-Resistant Disorders
FOCUS 2010;8:550-553.

Abstract

This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field and members of the editorial and advisory boards. Entries are listed chronologically and within years by first author. Articles from the bibliography that are reprinted in this issue are in bold type.

Abstract Teaser
Figures in this Article

Aberg K, Adkins DE, Bukszár J, Webb BT, Caroff SN, Miller del D, Sebat J, Stroup S, Fanous AH, Vladimirov VI, McClay JL, Lieberman JA, Sullivan PF, van den Oord EJ: Genomewide association study of movement-related adverse antipsychotic effects.  Biol Psychiatry 2010; 67:279—282
[PubMed]
[CrossRef]
 
Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H: Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.  Int J Neuropsychopharmacol 2010; 13:305—320
[PubMed]
[CrossRef]
 
Bewernick BH, Hurlemann R, Matusch A, Kayser S, Grubert C, Hadrysiewicz B, Axmacher N, Lemke M, Cooper-Mahkorn D, Cohen MX, Brockmann H, Lenartz D, Sturm V, Schlaepfer TE: Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression.  Biol Psychiatry 2010; 67:110—116
[PubMed]
[CrossRef]
 
Binder EB, Owens MJ, Liu W, Deveau TC, Rush AJ, Trivedi MH, Fava M, Bradley B, Ressler KJ, Nemeroff CB: Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.  Arch Gen Psychiatry 2010; 67:369—379
[PubMed]
[CrossRef]
 
Blanco C, Heimberg RG, Schneier FR, Fresco DM, Chen H, Turk CL, Vermes D, Erwin BA, Schmidt AB, Juster HR, Campeas R, Liebowitz MR: A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder.  Arch Gen Psychiatry 2010; 67:286—295
[PubMed]
[CrossRef]
 
George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE 3rd, Schwartz T, Sackeim HA: Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial.  Arch Gen Psychiatry 2010; 67:507—516
[PubMed]
[CrossRef]
 
Goodman WK, Foote KD, Greenberg BD, Ricciuti N, Bauer R, Ward H, Shapira NA, Wu SS, Hill CL, Rasmussen SA, Okun MS: Deep brain stimulation for intractable obsessive compulsive disorder: pilot study using a blinded, staggered-onset design.  Biol Psychiatry 2010; 67:535—542
[PubMed]
[CrossRef]
 
Nahas Z, Anderson BS, Borckardt J, Arana AB, George MS, Reeves ST, Takacs I: Bilateral epidural prefrontal cortical stimulation for treatment-resistant depression.  Biol Psychiatry 2010; 67:101—109
[PubMed]
[CrossRef]
 
Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, Hofmann SG, Eisenmenger K, Krystal JH, Pollack MH: Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder.  Biol Psychiatry 2010; 67:365—370
[PubMed]
[CrossRef]
 
Practice Guideline for the Treatment of Patients with Major Depressive Disorder 3rd ed.  American Psychiatric Association , 2010. http://www.psych.org/guidelines/mdd2010
 
Sarkhel S, Sinha VK, Praharaj SK: Adjunctive high-frequency right prefrontal repetitive transcranial magnetic stimulation (rTMS) was not effective in obsessive-compulsive disorder but improved secondary depression.  J Anxiety Disord 2010; 24:535—539
[PubMed]
[CrossRef]
 
Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Zagar T, Czerski PM, Jerman B, Larsen ER, Schulze TG, Zobel A, Cohen-Woods S, Pirlo K, Butler AW, Muglia P, Barnes MR, Lathrop M, Farmer A, Breen G, Aitchison KJ, Craig I, Lewis CM, McGuffin P: Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.  Am J Psychiatry 2010; 167:555—564
[PubMed]
[CrossRef]
 
van Apeldoorn FJ, Timmerman ME, Mersch PP, van Hout WJ, Visser S, van Dyck R, den Boer JA: A randomized trial of cognitive-behavioral therapy or selective serotonin reuptake inhibitor or both combined for panic disorder with or without agoraphobia: treatment results through 1-year follow-up.  J Clin Psychiatry 2010; 71:574—586
[PubMed]
[CrossRef]
 
Amir N, Beard C, Taylor CT, Klumpp H, Elias J, Burns M, Chen X: Attention training in individuals with generalized social phobia: a randomized controlled trial.  J Consult Clin Psychol 2009; 77:961—973
[PubMed]
[CrossRef]
 
Amir N, Beard C, Taylor CT, Klumpp H, Elias J, Burns M, Chen X: The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.  Eur Arch Psychiatry Clin Neurosci 2009; 259:172—185
[PubMed]
[CrossRef]
 
Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, Kerse N, Macgillivray S: Antidepressants versus placebo for depression in primary care.  Cochrane Database Syst Rev 2009; CD007954
 
Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.  Lancet 2009; 373:746—758
[PubMed]
[CrossRef]
 
Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.  Am J Psychiatry 2009; 166:152—163
[PubMed]
[CrossRef]
 
Malone DA Jr, Dougherty DD, Rezai AR, Carpenter LL, Friehs GM, Eskandar EN, Rauch SL, Rasmussen SA, Machado AG, Kubu CS, Tyrka AR, Price LH, Stypulkowski PH, Giftakis JE, Rise MT, Malloy PF, Salloway SP, Greenberg BD: Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression.  Biol Psychiatry 2009; 65:267—275
[PubMed]
[CrossRef]
 
Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ: A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.  J Clin Psychiatry 2009; 70:863—868
[PubMed]
[CrossRef]
 
Nelson JC, Papakostas GI: Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166:980—991
[PubMed]
[CrossRef]
 
Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, McEvoy J, Lieberman J: Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial.  Schizophr Res 2009; 107:22—29
[PubMed]
[CrossRef]
 
Schutter DJ: Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis.  Psychol Med 2009; 39:65—75
[PubMed]
[CrossRef]
 
Simon NM, Otto MW, Worthington JJ, Hoge EA, Thompson EH, Lebeau RT, Moshier SJ, Zalta AK, Pollack MH: Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial.  J Clin Psychiatry 2009; 70:1563—1570
[PubMed]
[CrossRef]
 
Tiihonen J, Wahlbeck K, Kiviniemi V: The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis.  Schizophr Res 2009; 109:10—14
[PubMed]
[CrossRef]
 
Watanabe N, Churchill R, Furukawa TA: Combined psychotherapy plus benzodiazepines for panic disorder.  Cochrane Database Syst Rev 2009; CD005335
 
Yood MU, DeLorenze G, Quesenberry CP Jr, Oliveria SA, Tsai AL, Willey VJ, McQuade R, Newcomer J, L'Italien G: The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic study.  Pharmacoepidemiol Drug Saf 2009; 18:791—799
[PubMed]
[CrossRef]
 
Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC, Mercer KB, Tang Y, Gillespie CF, Heim CM, Nemeroff CB, Schwartz AC, Cubells JF, Ressler KJ: Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults.  JAMA 2008; 299:1291—1305
[PubMed]
[CrossRef]
 
Bradley RG, Binder EB, Epstein MP, Tang Y, Nair HP, Liu W, Gillespie CF, Berg T, Evces M, Newport DJ, Stowe ZN, Heim CM, Nemeroff CB, Schwartz A, Cubells JF, Ressler KJ:. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene.  Arch Gen Psychiatry 2008; 65:190—200
[PubMed]
[CrossRef]
 
Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, Kim YS: Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial.  J Clin Psychiatry 2008; 69:720—731
[PubMed]
[CrossRef]
 
de Maat S, Dekker J, Schoevers R, van Aalst G, Gijsbers-van Wijk C, Hendriksen M, Kool S, Peen J, Van R, and de Jonghe F: Short psychodynamic supportive psychotherapy, antidepressants, and their combination in the treatment of major depression: a mega-analysis based on three randomized clinical trials.  Depress Anxiety 2008; 25:565—574
[PubMed]
[CrossRef]
 
Fitzgerald PB, Daskalakis ZJ: A review of repetitive transcranial magnetic stimulation use in the treatment of schizophrenia.  Can J Psychiatry 2008; 53:567—576
[PubMed]
 
Lozano AM, Mayberg HS, Giacobbe P, Hamani C, Craddock RC, Kennedy SH: Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry 2008; 64:461—467
[PubMed]
[CrossRef]
 
Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yağcioğlu AE, Small JG: A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.  J Clin Psychiatry 2008; 69:274—285
[PubMed]
[CrossRef]
 
Nelson JC, Delucchi K, Schneider LS: The efficacy of second generation antidepressants in late life depression: a meta-analysis. Am J Geriatric Psychiatry 2008; 16:558—567
[CrossRef]
 
Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME: Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008; 63:424—434
[PubMed]
[CrossRef]
 
Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD: A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.  J Clin Psychiatry 2008; 69:1046—1056
[PubMed]
[CrossRef]
 
Pollack MH, Otto MW, Roy-Byrne PP, Coplan JD, Rothbaum BO, Simon NM, Gorman JM: Novel treatment approaches for refractory anxiety disorders. Depress Anxiety 2008; 25:467—476. Reprinted in Focus 2008; 6:486—495
[PubMed]
[CrossRef]
 
Rathod S, Kingdon D, Weiden P, Turkington D: Cognitive-behavioral therapy for medication-resistant schizophrenia: a review. J Psychiatr Pract 2008; 14:22—33
[PubMed]
[CrossRef]
 
Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, Vermes D, Schmidt AB, Hembree E, Franklin M, Campeas R, Hahn CG, Petkova E: A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry 2008; 165:621—630
[PubMed]
[CrossRef]
 
Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross C, Peskind ER, Raskind MA: Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study.  Biol Psychiatry 2008; 63:629—632
[PubMed]
[CrossRef]
 
Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy.  N Engl J Med 2008; 358:252—260
[PubMed]
[CrossRef]
 
Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE: Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.  Neuropsychopharmacology 2008; 33:985—994
[PubMed]
[CrossRef]
 
Yood MU, DeLorenze G, Quesenberry CP Jr, Oliveria SA, Tsai AL, Willey VJ, McQuade R, Newcomer J, L'Italien G: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders—first revision.  World J Biol Psychiatry 2008; 9:248—312
[PubMed]
[CrossRef]
 
Gartlehner G, Hansen RA, Thieda P, DeVeaugh-Geiss AM, Gaynes BN, Krebs EE, Lux LJ, Morgan LC, Shumate JA, Monroe LG, Lohr KN: Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression.  Comparative Effectiveness Review No. 7 (Prepared by RTI International-University of North Carolina Evidence-based Practice Center) .  Rockville, MD,  Agency for Healthcare Research and Quality, 2007. http://www.effectivehealthcare.ahrq.gov/reports/final.cfm
 
Institute of Medicine:  Treatment of PTSD: an assessment of the evidence .  Washington, DC,  National Academies Press, 2007
 
Mitelman SA, Buchsbaum MS: Very poor outcome schizophrenia: clinical and neuroimaging aspects.  Int Rev Psychiatry 2007; 19:345—357
[PubMed]
[CrossRef]
 
O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery D, Fitzgerald PB, Loo C, Demitrack MA, George MS, Sackeim HA: Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial.  Biol Psychiatry 2007; 62:1208—1216
[PubMed]
[CrossRef]
 
Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, Shofer J, O'Connell J, Taylor F, Gross C, Rohde K, McFall ME: A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder.  Biol Psychiatry 2007; 61:928—934
[PubMed]
[CrossRef]
 
Shekelle P, Maglione M, Bagley S, Suttorp M, Mojica WA, Carter J, Rolon C, Hilton L, Zhou A, Chen S, Glassman P: Comparative effectiveness of off-label use of atypical antipsychotics.  Comparative Effectiveness Review No. 6 (prepared by the Southern California/RAND Evidence-Based Practice Center) .  Rockville, MD,  Agency for Healthcare Research and Quality, 2007
 
Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R: Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial.  Schizophr Res 2007; 92:90—94
[PubMed]
[CrossRef]
 
Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW: Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry 2006; 163:418—425
[PubMed]
[CrossRef]
 
Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW: Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.  J Clin Psychiatry 2006; 67:453—460
[PubMed]
[CrossRef]
 
Bystritsky A: Treatment-resistant anxiety disorders.  Mol Psychiatry 2006 ; 11:805—814
[PubMed]
[CrossRef]
 
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.  Am J Psychiatry 2006; 163:1905—1917. Reprinted in Focus 2008; 6:128—142
[PubMed]
[CrossRef]
 
Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwalb JM, Kennedy SH: Deep brain stimulation for treatment-resistant depression.  Neuron 2005; 45:651—660. Reprinted in Focus 2008; 6:143—154
[PubMed]
[CrossRef]
 
Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, Cooke RG: Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.  Biol Psychiatry 2005; 58:347—354
[PubMed]
[CrossRef]
 
Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, Lavori P, Howland R, Kling MA, Rittberg B, Carpenter L, Ninan P, Moreno F, Schwartz T, Conway C, Burke M, Barry JJ: Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study.  Biol Psychiatry 2005; 58:355—363
[PubMed]
[CrossRef]
 
Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, Naito S, Shimizu T, Itoh K, Inoue K, Suzuki T, Nemeroff CB: Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004; 161:1575—1580
[PubMed]
[CrossRef]
 
Hollander E, Baldini Rossi N, Sood E, Pallanti S: Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.  Int J Neuropsychopharmacol 2003; 6:397—401
[PubMed]
[CrossRef]
 
Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, McCullough JP Jr, Weiss PM, Dunner DL, Rothbaum BO, Kornstein S, Keitner G, Keller MB: Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.  Proc Natl Acad Sci USA 2003; 100:14293—14296. Reprinted in Focus 2005; 3:131—135
[PubMed]
[CrossRef]
 
References Container
+

References

Aberg K, Adkins DE, Bukszár J, Webb BT, Caroff SN, Miller del D, Sebat J, Stroup S, Fanous AH, Vladimirov VI, McClay JL, Lieberman JA, Sullivan PF, van den Oord EJ: Genomewide association study of movement-related adverse antipsychotic effects.  Biol Psychiatry 2010; 67:279—282
[PubMed]
[CrossRef]
 
Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H: Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.  Int J Neuropsychopharmacol 2010; 13:305—320
[PubMed]
[CrossRef]
 
Bewernick BH, Hurlemann R, Matusch A, Kayser S, Grubert C, Hadrysiewicz B, Axmacher N, Lemke M, Cooper-Mahkorn D, Cohen MX, Brockmann H, Lenartz D, Sturm V, Schlaepfer TE: Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression.  Biol Psychiatry 2010; 67:110—116
[PubMed]
[CrossRef]
 
Binder EB, Owens MJ, Liu W, Deveau TC, Rush AJ, Trivedi MH, Fava M, Bradley B, Ressler KJ, Nemeroff CB: Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.  Arch Gen Psychiatry 2010; 67:369—379
[PubMed]
[CrossRef]
 
Blanco C, Heimberg RG, Schneier FR, Fresco DM, Chen H, Turk CL, Vermes D, Erwin BA, Schmidt AB, Juster HR, Campeas R, Liebowitz MR: A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder.  Arch Gen Psychiatry 2010; 67:286—295
[PubMed]
[CrossRef]
 
George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE 3rd, Schwartz T, Sackeim HA: Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial.  Arch Gen Psychiatry 2010; 67:507—516
[PubMed]
[CrossRef]
 
Goodman WK, Foote KD, Greenberg BD, Ricciuti N, Bauer R, Ward H, Shapira NA, Wu SS, Hill CL, Rasmussen SA, Okun MS: Deep brain stimulation for intractable obsessive compulsive disorder: pilot study using a blinded, staggered-onset design.  Biol Psychiatry 2010; 67:535—542
[PubMed]
[CrossRef]
 
Nahas Z, Anderson BS, Borckardt J, Arana AB, George MS, Reeves ST, Takacs I: Bilateral epidural prefrontal cortical stimulation for treatment-resistant depression.  Biol Psychiatry 2010; 67:101—109
[PubMed]
[CrossRef]
 
Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, Hofmann SG, Eisenmenger K, Krystal JH, Pollack MH: Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder.  Biol Psychiatry 2010; 67:365—370
[PubMed]
[CrossRef]
 
Practice Guideline for the Treatment of Patients with Major Depressive Disorder 3rd ed.  American Psychiatric Association , 2010. http://www.psych.org/guidelines/mdd2010
 
Sarkhel S, Sinha VK, Praharaj SK: Adjunctive high-frequency right prefrontal repetitive transcranial magnetic stimulation (rTMS) was not effective in obsessive-compulsive disorder but improved secondary depression.  J Anxiety Disord 2010; 24:535—539
[PubMed]
[CrossRef]
 
Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Zagar T, Czerski PM, Jerman B, Larsen ER, Schulze TG, Zobel A, Cohen-Woods S, Pirlo K, Butler AW, Muglia P, Barnes MR, Lathrop M, Farmer A, Breen G, Aitchison KJ, Craig I, Lewis CM, McGuffin P: Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.  Am J Psychiatry 2010; 167:555—564
[PubMed]
[CrossRef]
 
van Apeldoorn FJ, Timmerman ME, Mersch PP, van Hout WJ, Visser S, van Dyck R, den Boer JA: A randomized trial of cognitive-behavioral therapy or selective serotonin reuptake inhibitor or both combined for panic disorder with or without agoraphobia: treatment results through 1-year follow-up.  J Clin Psychiatry 2010; 71:574—586
[PubMed]
[CrossRef]
 
Amir N, Beard C, Taylor CT, Klumpp H, Elias J, Burns M, Chen X: Attention training in individuals with generalized social phobia: a randomized controlled trial.  J Consult Clin Psychol 2009; 77:961—973
[PubMed]
[CrossRef]
 
Amir N, Beard C, Taylor CT, Klumpp H, Elias J, Burns M, Chen X: The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.  Eur Arch Psychiatry Clin Neurosci 2009; 259:172—185
[PubMed]
[CrossRef]
 
Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, Kerse N, Macgillivray S: Antidepressants versus placebo for depression in primary care.  Cochrane Database Syst Rev 2009; CD007954
 
Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C: Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.  Lancet 2009; 373:746—758
[PubMed]
[CrossRef]
 
Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.  Am J Psychiatry 2009; 166:152—163
[PubMed]
[CrossRef]
 
Malone DA Jr, Dougherty DD, Rezai AR, Carpenter LL, Friehs GM, Eskandar EN, Rauch SL, Rasmussen SA, Machado AG, Kubu CS, Tyrka AR, Price LH, Stypulkowski PH, Giftakis JE, Rise MT, Malloy PF, Salloway SP, Greenberg BD: Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression.  Biol Psychiatry 2009; 65:267—275
[PubMed]
[CrossRef]
 
Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ: A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.  J Clin Psychiatry 2009; 70:863—868
[PubMed]
[CrossRef]
 
Nelson JC, Papakostas GI: Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166:980—991
[PubMed]
[CrossRef]
 
Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, McEvoy J, Lieberman J: Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial.  Schizophr Res 2009; 107:22—29
[PubMed]
[CrossRef]
 
Schutter DJ: Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis.  Psychol Med 2009; 39:65—75
[PubMed]
[CrossRef]
 
Simon NM, Otto MW, Worthington JJ, Hoge EA, Thompson EH, Lebeau RT, Moshier SJ, Zalta AK, Pollack MH: Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial.  J Clin Psychiatry 2009; 70:1563—1570
[PubMed]
[CrossRef]
 
Tiihonen J, Wahlbeck K, Kiviniemi V: The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis.  Schizophr Res 2009; 109:10—14
[PubMed]
[CrossRef]
 
Watanabe N, Churchill R, Furukawa TA: Combined psychotherapy plus benzodiazepines for panic disorder.  Cochrane Database Syst Rev 2009; CD005335
 
Yood MU, DeLorenze G, Quesenberry CP Jr, Oliveria SA, Tsai AL, Willey VJ, McQuade R, Newcomer J, L'Italien G: The incidence of diabetes in atypical antipsychotic users differs according to agent—results from a multisite epidemiologic study.  Pharmacoepidemiol Drug Saf 2009; 18:791—799
[PubMed]
[CrossRef]
 
Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC, Mercer KB, Tang Y, Gillespie CF, Heim CM, Nemeroff CB, Schwartz AC, Cubells JF, Ressler KJ: Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults.  JAMA 2008; 299:1291—1305
[PubMed]
[CrossRef]
 
Bradley RG, Binder EB, Epstein MP, Tang Y, Nair HP, Liu W, Gillespie CF, Berg T, Evces M, Newport DJ, Stowe ZN, Heim CM, Nemeroff CB, Schwartz A, Cubells JF, Ressler KJ:. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene.  Arch Gen Psychiatry 2008; 65:190—200
[PubMed]
[CrossRef]
 
Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, Kim YS: Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial.  J Clin Psychiatry 2008; 69:720—731
[PubMed]
[CrossRef]
 
de Maat S, Dekker J, Schoevers R, van Aalst G, Gijsbers-van Wijk C, Hendriksen M, Kool S, Peen J, Van R, and de Jonghe F: Short psychodynamic supportive psychotherapy, antidepressants, and their combination in the treatment of major depression: a mega-analysis based on three randomized clinical trials.  Depress Anxiety 2008; 25:565—574
[PubMed]
[CrossRef]
 
Fitzgerald PB, Daskalakis ZJ: A review of repetitive transcranial magnetic stimulation use in the treatment of schizophrenia.  Can J Psychiatry 2008; 53:567—576
[PubMed]
 
Lozano AM, Mayberg HS, Giacobbe P, Hamani C, Craddock RC, Kennedy SH: Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry 2008; 64:461—467
[PubMed]
[CrossRef]
 
Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yağcioğlu AE, Small JG: A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.  J Clin Psychiatry 2008; 69:274—285
[PubMed]
[CrossRef]
 
Nelson JC, Delucchi K, Schneider LS: The efficacy of second generation antidepressants in late life depression: a meta-analysis. Am J Geriatric Psychiatry 2008; 16:558—567
[CrossRef]
 
Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME: Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008; 63:424—434
[PubMed]
[CrossRef]
 
Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD: A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.  J Clin Psychiatry 2008; 69:1046—1056
[PubMed]
[CrossRef]
 
Pollack MH, Otto MW, Roy-Byrne PP, Coplan JD, Rothbaum BO, Simon NM, Gorman JM: Novel treatment approaches for refractory anxiety disorders. Depress Anxiety 2008; 25:467—476. Reprinted in Focus 2008; 6:486—495
[PubMed]
[CrossRef]
 
Rathod S, Kingdon D, Weiden P, Turkington D: Cognitive-behavioral therapy for medication-resistant schizophrenia: a review. J Psychiatr Pract 2008; 14:22—33
[PubMed]
[CrossRef]
 
Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, Vermes D, Schmidt AB, Hembree E, Franklin M, Campeas R, Hahn CG, Petkova E: A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry 2008; 165:621—630
[PubMed]
[CrossRef]
 
Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross C, Peskind ER, Raskind MA: Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study.  Biol Psychiatry 2008; 63:629—632
[PubMed]
[CrossRef]
 
Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy.  N Engl J Med 2008; 358:252—260
[PubMed]
[CrossRef]
 
Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE: Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.  Neuropsychopharmacology 2008; 33:985—994
[PubMed]
[CrossRef]
 
Yood MU, DeLorenze G, Quesenberry CP Jr, Oliveria SA, Tsai AL, Willey VJ, McQuade R, Newcomer J, L'Italien G: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders—first revision.  World J Biol Psychiatry 2008; 9:248—312
[PubMed]
[CrossRef]
 
Gartlehner G, Hansen RA, Thieda P, DeVeaugh-Geiss AM, Gaynes BN, Krebs EE, Lux LJ, Morgan LC, Shumate JA, Monroe LG, Lohr KN: Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression.  Comparative Effectiveness Review No. 7 (Prepared by RTI International-University of North Carolina Evidence-based Practice Center) .  Rockville, MD,  Agency for Healthcare Research and Quality, 2007. http://www.effectivehealthcare.ahrq.gov/reports/final.cfm
 
Institute of Medicine:  Treatment of PTSD: an assessment of the evidence .  Washington, DC,  National Academies Press, 2007
 
Mitelman SA, Buchsbaum MS: Very poor outcome schizophrenia: clinical and neuroimaging aspects.  Int Rev Psychiatry 2007; 19:345—357
[PubMed]
[CrossRef]
 
O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery D, Fitzgerald PB, Loo C, Demitrack MA, George MS, Sackeim HA: Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial.  Biol Psychiatry 2007; 62:1208—1216
[PubMed]
[CrossRef]
 
Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, Shofer J, O'Connell J, Taylor F, Gross C, Rohde K, McFall ME: A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder.  Biol Psychiatry 2007; 61:928—934
[PubMed]
[CrossRef]
 
Shekelle P, Maglione M, Bagley S, Suttorp M, Mojica WA, Carter J, Rolon C, Hilton L, Zhou A, Chen S, Glassman P: Comparative effectiveness of off-label use of atypical antipsychotics.  Comparative Effectiveness Review No. 6 (prepared by the Southern California/RAND Evidence-Based Practice Center) .  Rockville, MD,  Agency for Healthcare Research and Quality, 2007
 
Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R: Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial.  Schizophr Res 2007; 92:90—94
[PubMed]
[CrossRef]
 
Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW: Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry 2006; 163:418—425
[PubMed]
[CrossRef]
 
Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW: Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.  J Clin Psychiatry 2006; 67:453—460
[PubMed]
[CrossRef]
 
Bystritsky A: Treatment-resistant anxiety disorders.  Mol Psychiatry 2006 ; 11:805—814
[PubMed]
[CrossRef]
 
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.  Am J Psychiatry 2006; 163:1905—1917. Reprinted in Focus 2008; 6:128—142
[PubMed]
[CrossRef]
 
Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwalb JM, Kennedy SH: Deep brain stimulation for treatment-resistant depression.  Neuron 2005; 45:651—660. Reprinted in Focus 2008; 6:143—154
[PubMed]
[CrossRef]
 
Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, Cooke RG: Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.  Biol Psychiatry 2005; 58:347—354
[PubMed]
[CrossRef]
 
Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, Lavori P, Howland R, Kling MA, Rittberg B, Carpenter L, Ninan P, Moreno F, Schwartz T, Conway C, Burke M, Barry JJ: Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study.  Biol Psychiatry 2005; 58:355—363
[PubMed]
[CrossRef]
 
Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, Naito S, Shimizu T, Itoh K, Inoue K, Suzuki T, Nemeroff CB: Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004; 161:1575—1580
[PubMed]
[CrossRef]
 
Hollander E, Baldini Rossi N, Sood E, Pallanti S: Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.  Int J Neuropsychopharmacol 2003; 6:397—401
[PubMed]
[CrossRef]
 
Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, McCullough JP Jr, Weiss PM, Dunner DL, Rothbaum BO, Kornstein S, Keitner G, Keller MB: Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.  Proc Natl Acad Sci USA 2003; 100:14293—14296. Reprinted in Focus 2005; 3:131—135
[PubMed]
[CrossRef]
 
References Container
+
+

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 1.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 9.  >
Psychiatric News
Read more at Psychiatric News >>
PubMed Articles
Obsessive-compulsive disorder. J Pharm Pract 2014;27(2):116-30.